Specialty Pharma Journal Specialty, Precision & Technology
Boehringer Ingelheim and Autifony Therapeutics Limited (“Autifony”) today announced that they have signed an agreement about certain aspects of Autifony’s voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform. Included in the agreement is the lead compound AUT00206, a …
Tag Archives: Central Nervous System Disorders
December, 2017
April, 2015
-
15 April
New Drug Shows Potential in Reversing the Damage from Multiple Sclerosis
In a mid-stage trial, Biogen’s experimental drug has shown the potential to reverse nerve damage seen in multiple sclerosis (MS) patients. MS is an often disabling disease of the central nervous system (CNS). The disease attacks the protective sheath, known as the myelin, which covers the nerves. Myelin damage disrupts …
March, 2015
-
30 March
Teva Strengthens its CNS Portfolio with its $3.2 Billion Acquisition of Auspex
Today, Teva Pharmaceutical Industries Ltd. announced that it has agreed to acquire central nervous system (CNS) drug developer Auspex Pharmaceuticals, Inc. for about $3.2 billion. The companies said that they have entered into a definitive merger agreement, under which Teva will commence a tender offer for all of the outstanding …